About the Organ Transplantation Center

We are currently enrolling for the following studies:

E5501 Thrombocytopenia : (E5501-G000-202)
Sponsor: Eisai Inc
A Phase 2, Randomized, Multicenter, Placebo-controlled, Double-Blind, Parallel-Group Study to Evaluate the Efficacy, Safety and Population Pharmacokinetics of Once-Daily Oral E5501 Tablets Used up to 7-days in Subjects with Chronic Liver Diseases and Thrombocytopenia Prior to Elective Surgical or Diagnostic Procedures.

Group A: 100 mg E5501 + 20 mg E5501
Group B: 100 mg E5501 + 40 mg E5501
Group C: 100 mg E5501 + 80 mg E5501
Group D: Placebo

ELAD: (VTI-206)
Sponsor: Vital Therapies
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD®) in Subjects with Acute on Chronic Hepatitis (AOCH)

Group 1: ELAD THERAPY
Group 2: W/O ELAD THERAPY

HepaGam (HB-009)

Sponsor: Cangene
Evaluation of HepaGam B in combination with antiviral treatment in Hepatitis B liver transplant patients

One Group: HepaGam B™ +Antiviral Treatment.